The Impact of Comorbidities on the Treatment Outcome in Patients With Severe Covid-19-Associated Pneumonia

BACKGROUND. A significant role in the course and outcome of COVID-19, alongside other clinical and laboratory factors, is played by comorbidities.

THE AIM OF THE STUDY. We studied the impact of comorbidities on the course and outcomes of severe COVID-19-associated pneumonia.

MATERIAL AND METHODS. The study was conducted at the Yakut Republican Clinical Hospital. We analyzed treatment outcomes of 450 patients with severe COVID-19-associated pneumonia who were hospitalized in the intensive care unit. An observational case-control study was conducted, in accordance with the research objective, comorbidities were analyzed in detail in two groups of patients: survivors — 144 (32.0%) and deceased — 306 (68.0%). The endpoint of the study was a fatal outcome. The modified Charlson comorbidity index was used to assess the patients’ comorbidity status.

RESULTS. The study revealed the presence of concomitant pathology in 446 (99.1%) patients. 57 (12.7%) patients had two concomitant diseases, 369 (82%) patients had three or more pathologies. A statistically significant impact on the risk of death for the following combinations of comorbid conditions were found: chronic central nervous system diseases with chronic kidney disease; hypertension with chronic kidney disease; coronary heart disease with chronic kidney disease; severe obesity (class III) with coronary heart disease and chronic kidney disease; severe obesity (class III) with type 2 diabetes mellitus. The mortality rate of patients increases linearly with the growth of the Charlson comorbidity index (p<0.001).

CONCLUSION. The obtained data indicate a significant increase in the risk of death in patients with severe COVID-19-associated pneumonia in the presence of comorbidities. Therefore, when predicting the outcome and improving the treatment results of this category of patients, one should take into account the patient’s comorbidity.

1. Feinstein AR. Pre-therapeutic classification of co-morbidity in chronic disease. J Chron Dis. 1970;23(7):455–468. PMID: 26309916 http://doi.org/10.1016/0021-9681(70)90054-8

2. Glybochko P, Fomin V, Moiseev S, Avdeev S, Yavorovskiy A, Brovko M, et al. Clinical outcomes of patients with COVID-19 admitted for respiratory support to the intensive care units in Russia. Clin Pharmacol Ther. 2020;29(3):25–36 (In Russ.). http://doi.org/10.32756/0869-5490-2020-3-25-36

3. Pfortmueller CA, Spinetti T, Urman RD, Luedi MM, Schefold JC. COVID-19-associated acute respiratory distress syndrome (CARDS): Current knowledge on pathophysiology and ICU treatment – A narrative review. Best Pract Res Clin Anaesthesiol. 2021;35(3):351–368. PMID: 34511224 http://doi.org/10.1016/j.bpa.2020.12.011

4. Grinevich VB, Gubonina IV, Doshchitsin VL, Kotovskaya YuV, Kravchuk YuA, Ped VI, et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention. 2020;19(4):2630. (In Russ.) https://doi.org/10.15829/1728-8800-2020-2630

5. Profilaktika, diagnostika i lechenie novoy koronavirusnoy infektsii (COVID-19): vremennye metodicheskie rekomendatsii. Versiya 17 (14.12.2022). Moscow; 2022. (In Russ.)

6. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613–619. PMID: 1607900 http://doi.org/10.1016/0895-4356(92)90133-8

7. Barbarash OL, Karetnikova VN, Kashtalap VV, Zvereva TN, Kochergina AM. New coronavirus disease (COVID-19) and cardiovascular disease. Complex Issues of Cardiovascular Diseases. 2020;9(2):17–28. (In Russ.) https://doi.org/10.17802/2306-1278-2020-9-2-17-28

8. Khairy Y, Naghibi D, Moosavi A, Sardareh M, Azami-Aghdash S. Prevalence of hypertension and associated risks in hospitalized patients with COVID-19: a meta-analysis of meta-analyses with 1468 studies and 1,281,510 patients. Syst Rev. 2022;11(1):242. PMID: 36397129 http://doi.org/10.1186/s13643-022-02111-2

9. Fang X, Li S, Yu H, Wang P, Zhang Y, Chen Z, et al. Epidemiological, comorbidity factors with severity and prognosis of COVID-19: A systematic review and meta-analysis. Aging (Albany NY). 2020;12(13):12493–12503. PMID: 32658868 http://doi.org/10.18632/aging.103579

10. Kunutsor SК, Laukkanen JA. Renal complications in COVID-19: a systematic review and meta-analysis. Ann Med. 2020;52(7):345–353. PMID: 32643418 http://doi.org/10.1080/07853890.2020.1790643

11. Bae SA, Kim SR, Kim MN, Shim WJ, Park SM. Impact of cardiovascular disease and risk factors on fatal outcomes in patients with COVID-19 according to age: а systematic review and meta-analysis. Heart. 2021;107(5):373–380. PMID: 33334865 http://doi.org/10.1136/heartjnl-2020-317901

12. Cohen JF, Korevaar DA, Matczak S, Chalumeau M, Allali S, Toubiana J. COVID-19–Related fatalities and intensive-care-unit admissions by age groups in Europe: A meta-analysis. Front Med. 2021;7:1–5. PMID: 33521004 http://doi.org/10.3389/fmed.2020.560685

13. O’Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings D.A.T, Azman AS, Paireau J, et. al. Age-specific mortality and immunity patterns of SARS-CoV-2. Nature. 2021;590(7844):140–145. PMID: 33137809 http://doi.org/10.1038/s41586-020-2918-0

14. Zhdankina NV, Frolov AG, Vilkova OE. Metabolic Syndrome and Covid-19: Mutual Influence (Review). Meditsinskiy Al’manakh. 2022;1(70):6–11. (In Russ.)